Malignancy Rates Remain Stable in Ustekinumab-Treated Patients - Skin and Allergy News Digital Network

Skin and hypersensitivity reaction News Digital Network disease Rates Remain Stable in Ustekinumab-Treated Patients Skin and Allergy News Digital system RIO GRANDE, PR – Malignancy rates in disease of the skin patients treated with ustekinumab did not increase significantly over 4 years of follow-up, based on pooled data from 3117 patients enrolled in ustekinumab clinical trials. and more » Link To Article